866319-07-5 Usage
Uses
Used in Pharmaceutical Industry:
(3aR,6aS)-tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione(SALTDATA: HCl 0.5H2O) is used as a pharmaceutical intermediate for its potential role in the synthesis of biologically active molecules. Its unique tetrahydropyrrolopyrrole ring structure and the presence of HCl and H2O components, which likely enhance its solubility in water, make it a promising candidate for the development of new drugs and therapeutic agents.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (3aR,6aS)-tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione(SALTDATA: HCl 0.5H2O) is utilized for studying its distinctive structure and exploring its potential biological activity. This research may contribute to the advancement of drug development by providing insights into the compound's properties and possible applications in creating new therapeutic agents.
Additional research is needed to fully understand the properties and potential applications of (3aR,6aS)-tetrahydropyrrolo[3,4-c]pyrrole-1,3(2H,3aH)-dione(SALTDATA: HCl 0.5H2O) in various industries.
Check Digit Verification of cas no
The CAS Registry Mumber 866319-07-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,6,3,1 and 9 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 866319-07:
(8*8)+(7*6)+(6*6)+(5*3)+(4*1)+(3*9)+(2*0)+(1*7)=195
195 % 10 = 5
So 866319-07-5 is a valid CAS Registry Number.
866319-07-5Relevant articles and documents
NOVEL TRIAZINE COMPOUNDS
-
Page/Page column 74-75, (2012/08/08)
The present invention relates to novel triazine compounds of formula (1), methods of their preparation, pharmaceutical compositions containing these compounds and the use of these compounds to treat proliferative disorders such as tumors and cancers and also other conditions and disorders related to or associated with dysregulation of PI3 Kinases, PI3 Kinase pathway, mTOR and/ or the mTOR pathway.
